Literature DB >> 25667511

Vitamin D inhibits ovarian cancer cell line proliferation in combination with celecoxib and suppresses cyclooxygenase-2 expression.

Marc Thill1, Alena Woeste2, Kathrin Reichert2, Dorothea Fischer2, Achim Rody2, Michael Friedrich3, Frank Köster4.   

Abstract

BACKGROUND: Vitamin D exhibits multiple anti-proliferative and pro-differentiating actions. Prostaglandin-(PG)E2 is a tumor-promoting tissue hormone anabolized by cyclooxygenase-2 (COX-2). Recently, a link between the PG and vitamin D metabolism was reported.
MATERIALS AND METHODS: The influence of calcitriol and celecoxib on the proliferation of ovarian cancer cell lines was measured and the impact of calcitriol on the protein and mRNA expression of COX-2 was quantified by western blot and qRT-PCR, respectively.
RESULTS: After COX-2 induction with interleukin (IL)-1β, 10 μM celecoxib did not significantly inhibit the proliferation of OVCAR-3 cells, whereas calcitriol showed such an effect; however, the combination of the two substances had an additive influence. After induction by IL-1β, calcitriol inhibited the COX-2 protein, as well as its mRNA expression significantly in OVCAR-3 and SKOV-3 cells.
CONCLUSION: These data suggest a correlation between PG and vitamin D metabolism in their anti-tumorigenic activity in ovarian carcinomas. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Vitamin D; celecoxib; cyclooxygenase-2; ovarian cancer

Mesh:

Substances:

Year:  2015        PMID: 25667511

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

Review 1.  The role of vitamin D in ovarian cancer: epidemiology, molecular mechanism and prevention.

Authors:  Hui Guo; Jing Guo; Wenli Xie; Lingqin Yuan; Xiugui Sheng
Journal:  J Ovarian Res       Date:  2018-08-29       Impact factor: 4.234

2.  Calcitriol and Calcidiol Can Sensitize Melanoma Cells to Low⁻LET Proton Beam Irradiation.

Authors:  Ewa Podgorska; Agnieszka Drzal; Zenon Matuszak; Jan Swakon; Andrzej Slominski; Martyna Elas; Krystyna Urbanska
Journal:  Int J Mol Sci       Date:  2018-07-31       Impact factor: 5.923

Review 3.  Vitamin D and Ovarian Cancer: Systematic Review of the Literature with a Focus on Molecular Mechanisms.

Authors:  Andraž Dovnik; Nina Fokter Dovnik
Journal:  Cells       Date:  2020-02-01       Impact factor: 6.600

4.  Association among Vitamin D, Retinoic Acid-Related Orphan Receptors, and Vitamin D Hydroxyderivatives in Ovarian Cancer.

Authors:  Anna A Brożyna; Tae-Kang Kim; Marzena Zabłocka; Wojciech Jóźwicki; Junming Yue; Robert C Tuckey; Anton M Jetten; Andrzej T Slominski
Journal:  Nutrients       Date:  2020-11-19       Impact factor: 5.717

5.  Cytoplasmic VDR expression as an independent risk factor for ovarian cancer.

Authors:  Bastian Czogalla; Eileen Deuster; Yue Liao; Doris Mayr; Elisa Schmoeckel; Cornelia Sattler; Thomas Kolben; Anna Hester; Sophie Fürst; Alexander Burges; Sven Mahner; Udo Jeschke; Fabian Trillsch
Journal:  Histochem Cell Biol       Date:  2020-06-22       Impact factor: 4.304

6.  Skin microbiome considerations for long haul space flights.

Authors:  Gabrielle Caswell; Ben Eshelby
Journal:  Front Cell Dev Biol       Date:  2022-09-08

7.  HIDEEP: a systems approach to predict hormone impacts on drug efficacy based on effect paths.

Authors:  Mijin Kwon; Jinmyung Jung; Hasun Yu; Doheon Lee
Journal:  Sci Rep       Date:  2017-11-30       Impact factor: 4.379

Review 8.  Vitamin D and VDR in Gynecological Cancers-A Systematic Review.

Authors:  Eileen Deuster; Udo Jeschke; Yao Ye; Sven Mahner; Bastian Czogalla
Journal:  Int J Mol Sci       Date:  2017-11-04       Impact factor: 5.923

9.  Vitamin D Suppresses Ovarian Cancer Growth and Invasion by Targeting Long Non-Coding RNA CCAT2.

Authors:  Liye Wang; Shuang Zhou; Bin Guo
Journal:  Int J Mol Sci       Date:  2020-03-27       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.